GlassScriptPhysician profile
John N Hamaty
NPI 1306838164
$6,758.67
in general payments reported to CMS, 2019-2025
34 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,252 · 2020: $1,081 · 2021: $1,168 · 2022: $1,198 · 2023: $416 · 2024: $495 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $990.75 | 2019-2023 | Amplatzer Amulet |
| Boston Scientific Corporation | $890.31 | 2019-2024 | Watchman Flx, Bodyguardian |
| Janssen Pharmaceuticals, INC | $867.45 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $854.71 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $611.66 | 2019-2023 | Lifevest |
| Amgen INC. | $491.70 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $308.05 | 2019-2023 | |
| Irhythm Technologies, INC. | $267.52 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $257.43 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $116.30 | 2019-2023 | Farxiga |
| Philips North America LLC | $110.50 | 2023-2024 | (5044) Mcot, (5050) Extended Holter |
| Merck Sharp & Dohme LLC | $94.07 | 2021-2023 | Verquvo |
| W. L. Gore & Associates, INC. | $81.33 | 2020-2021 | |
| Medtronic, INC. | $78.85 | 2021-2023 | Azure Xt Dr Mri Surescan |
| Esperion Therapeutics, INC. | $67.87 | 2020-2024 | Nexletol |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $67.29 | 2023-2025 | |
| Atricure, INC. | $66.71 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.78 | 2019-2024 | Jardiance |
| Preventice Services, LLC | $62.65 | 2021 | |
| Impulse Dynamics (USA) INC. | $53.19 | 2022-2025 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $50.87 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $49.42 | 2019 | |
| Janssen Biotech, INC. | $44.24 | 2023-2024 | Tremfya |
| Medtronic Vascular, INC. | $32.94 | 2019 | |
| Scpharmaceuticals INC. | $32.53 | 2024 | |
| Astellas Pharma US INC | $29.01 | 2019 | |
| Novo Nordisk INC | $26.83 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.44 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $13.17 | 2020 | |
| Angiodynamics, INC. | $12.52 | 2019 | |
| Ucb, INC. | $11.94 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.89 | 2019 | |
| Daiichi Sankyo INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hamaty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.